
Eli Lilly owes an Arizonan company royalties from insulin product sales, a US court has ruled, as reported by news organization Endpoint News. A trial is now likely.
The federal court in Arizona has reached the conclusion that Novo Nordisk-competitor Eli Lilly, which is based in the US, must pay royalities to the firm Research Corporation Technologies, which is headquartered in Tuscon, Arizona.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Fruergaard leveraging experience from Danish partnerships in key roles in Brussels
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.